Rajiv Patni is EVP, Chief R&D Officer of Reata Pharmaceuticals Inc.
Person profile
Latest filings (excl ownership)
No filings
Latest ownership filings
4
Quince Therapeutics, Inc.
7 Jun 24
4
Quince Therapeutics, Inc.
15 Feb 24
3
Quince Therapeutics, Inc.
15 Feb 24
4
REATA PHARMACEUTICALS INC
26 Sep 23
4
REATA PHARMACEUTICALS INC
14 Jun 23
3
REATA PHARMACEUTICALS INC
14 Jun 23
4
PORTOLA PHARMACEUTICALS INC
2 Jul 20
4
PORTOLA PHARMACEUTICALS INC
3 Mar 20
3
PORTOLA PHARMACEUTICALS INC
11 Feb 20
4
Adamas Pharmaceuticals Inc
10 Apr 19
Recent insider trades
| Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 Jun 24 | QNCX Quince Therapeutics | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.82 | 13,500 | 11.07 k | 13,500 |
| 15 Feb 24 | QNCX Quince Therapeutics | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.3 | 54,000 | 70.20 k | 54,000 |
| 26 Sep 23 | RETA Reata Pharmaceuticals | Class A common stock | Sale back to company | Dispose D | No | No | 0 | 45,000 | 0.00 | 0 |
| 26 Sep 23 | RETA Reata Pharmaceuticals | Employee Stock Option Class A common stock | Sale back to company | Dispose D | No | No | 99.12 | 90,000 | 8.92 mm | 0 |